About this event
The advent of PCR methods has enabled the detection and quantification of nucleic acids in small sample sizes. Just recently, PCR technologies were placed on the frontline in our fight against the COVID-19 pandemic, when RT-qPCR methods were deployed as part of the diagnostic testing response.
Additionally, digital PCR (dPCR) represents a major step forward in the absolute quantification of nucleic acids. This technology is particularly useful in low abundance targets. With applications in liquid biopsy, copy number variation detection and pathogen detection, this technology has the potential to heavily impact genomic research. However, challenges such as accuracy, reproducibility, assay optimization and translation can prevent the use of these technologies in the clinic.
Join us for this unique 3-part webinar series, as we highlight how next-generation PCR methods can impact modern science, and how we are addressing the challenges related to the use of these technologies.
11th March, 3pm GMT/ 4pm CET/ 10am EST
This webinar will cover how we are improving the ways we approach dPCR for various applications, and how we are addressing the challenges associated with the use of this technology.
Digital High-Resolution Melting for improved dPCR quantification and pathogen detection – Stephanie Fraley, Associate Professor, Bioengineering, UC San Diego
Comparison of digital PCR to NGS for monitoring mitochondrial carryover after nuclear transfer for in-vitro fertilization – Ward de Spiegelaere, Assistant Professor, University of Ghent
The naica® system – a flexible dPCR assay development platform - Jean Fatien, M.Eng. Biomed - R&D Scientist, Stilla Technologies
18th March, 3pm GMT/ 4pm CET/ 10am EST
dPCR is particularly helpful in helping to quantify nucleic acids at a low frequency. With isolating ctDNA from a simple blood draw being likened to finding a needle in a haystack, improving our ability to detect these biomarkers in blood can improve the way we diagnose and monitor cancers forever.
This webinar will focus on the applications of dPCR in liquid biopsies, as well as future developments for these to be used routinely.
Ensuring the reliability of ctDNA results for clinical applications - Valerie Taly, Group Leader, INSERM
Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors – Ed Schuuring, Professor of Molecular Oncological Pathology, University Medical Centre Groningen
The implementation of dPCR in liquid biopsy and its considerations - Daniel Lofgren, Market Development Manager, Digital PCR, EMEA, QIAGEN
25th March, 3pm GMT/ 4pm CET/ 10am EST
The COVID-19 pandemic has put a specific emphasis on the ability of genomic tracking of infectious diseases. When the pandemic began, PCR technologies were at the forefront of our fight to detect COVID-positive patients as part of the response to stop the spread of Coronavirus.
This webinar will focus on the diagnostic applications of PCR methods in infectious diseases, and how they are being optimised.
Interested in counting viruses and bacteria? – Mojca Milavec, Research Councillor, National Institute of Biology
Rapid nucleic acid diagnostics for SARS-CoV-2 – Setphen Bustin, Professor of Molecular Medicine, Anglia Ruskin University
ddPCR & NGS for viral genome copies determination. A case study - Luisa Marena, Senior Scientist – Head of Innovative Cell Line Characterization Lab, Merck
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.